BioCentury | Apr 1, 2020
Distillery Therapeutics

Two glycopeptides for drug-resistant Gram-positive infections

...disease INDICATION: Staphylococcus; Gram-positive bacterial infections The glycopeptides corbomycin and complestatin could treat methicillin- and daptomycin-resistant...
...hydrolases. Complestatin and corbymycin reduced the growth of a panel of Gram-positive bacteria including MRSA, daptomycin-resistant...
BioCentury | Sep 19, 2019
Targets & Mechanisms

Regeneron's new take on bispecifics: activating complement

...only targeting IsdB. The treatment was as effective at S. aureus clearance as antibiotics vancomycin, daptomycin...
BioCentury | Aug 14, 2019
Distillery Therapeutics

Antihelminthic compound bithionol could treat MRSA infection

...aureus strain with minimum inhibitory concentrations (MICs) of 1 μg/mL, comparable to the potency of daptomycin...
...vancomycin. At 10x MIC, the antihelminthic killed one of the MRSA strains as quickly as daptomycin...
BioCentury | Jun 28, 2018
Distillery Therapeutics

Infectious disease

...inhibited bacterial growth with minimum inhibitory concentrations (MICs) of 0.5-3 µg/ml, potency comparable to Cubicin daptomycin...
...Co. Inc., Novartis AG, Sumitomo Dainippon Pharma Co. Ltd. and TTY Biopharm Co. Ltd. market Cubicin...
BioCentury | May 25, 2018
Product R&D

Peptides step up

...“vancapticins,” with varying linker chemistries. The best were over 100-fold more potent than vancomycin or daptomycin...
...than vancomycin. They also exhibited less resistance over 20 days of bacterial culture compared with daptomycin...
...of Queensland, Brisbane, Australia References Blaskovich, M., et al. “Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant...
BioCentury | Dec 1, 2017
Clinical News

CHMP recommends pediatric label expansion for Merck's Cubicin

...EMA's CHMP recommended approval of a label expansion for Cubicin daptomycin (MK-3009) from Merck & Co...
...& Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Cubicin daptomycin (MK-3009) (formerly LY146032) Business: Infectious Elizabeth S. Eaton Cubicin daptomycin MK-3009 Cubist...
BioCentury | Feb 22, 2017
Distillery Techniques

Chemistry

...On the antibiotic Cubicin daptomycin, the method utilizing each of the three C-prenyltransferases produced prenylated Cubicin...
...lower minimum inhibitory concentration (MIC) values (0.1-0.3 µM, 0.03-0.09 µM and 0.2-0.5 µM, respectively) than Cubicin...
...Novartis AG , Sumitomo Dainippon Pharma Co. Ltd. and TTY Biopharm Co. Ltd. market Cubicin...
BioCentury | Nov 16, 2015
Company News

Merck, Pfizer infectious news

...of Appeals for the Federal Circuit upheld a district court decision that Merck’s antibiotic Cubicin daptomycin...
...to FDA for a generic version of Cubicin infringes the patent. The ‘071 patent covers Cubicin’s...
BioCentury | Nov 14, 2015
Company News

CAFC decision would allow Cubicin generics in 2016

...for the Federal Circuit upheld a district court decision to invalidate four patents covering Cubicin daptomycin...
...patents were to expire in 2019 and 2020. The CAFC affirmed the validity of one Cubicin...
...further review at the Federal Circuit or Supreme Court. The pharma recorded $805 million in Cubicin...
BioCentury | Nov 9, 2015
Clinical News

Cubicin daptomycin regulatory update

...EMA’s CHMP recommended approval of a label expansion for Cubicin daptomycin from Novartis to include patients...
...earlier this year (see BioCentury, Dec. 15, 2014). Novartis has rights to develop and market Cubicin...
...Kenilworth, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Cubicin daptomycin ( MK-3009 ) (formerly LY146032...
Items per page:
1 - 10 of 369